<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02173730</url>
  </required_header>
  <id_info>
    <org_study_id>1160.10</org_study_id>
    <nct_id>NCT02173730</nct_id>
  </id_info>
  <brief_title>BIBR 953 ZW in Healthy Elderly Subjects</brief_title>
  <official_title>Pharmacokinetics of BIBR 953 ZW After 150 mg of BIBR 1048 (Oral Pro-drug of BIBR 953) Administered as Capsule Twice Daily Over Seven Days With or Without Pantoprazole Co-treatment to Healthy Male and Female Elderly Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      To assess the steady state pharmacokinetic profile of BIBR 953 ZW after administration of
      BIBR 1048 to male and female elderly subjects, to assess pharmacokinetic gender differences.
      To assess the effect of coadministration of Pantoprazole on the bioavailability of BIBR 953
      ZW.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2002</start_date>
  <primary_completion_date type="Actual">February 2003</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUCτ,ss (area under the plasma concentration time curve during a dosing interval at steady state)</measure>
    <time_frame>Day 4 and 7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax,ss (maximum measured concentration of the analyse in plasma at steady state over a uniform dosing interval τ)</measure>
    <time_frame>Day 4 and 7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Aeτ,ss (amount of dose excreted in urine over one dosing interval at steady state)</measure>
    <time_frame>Day 4 and 7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>feτ,ss (percent of dose excreted in urine over one dosing interval at steady state)</measure>
    <time_frame>Day 4 and 7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-tz,ss (area under the plasma concentration time curve (AUC) from zero time (pre dose) to the time of the last quantifiable concentration (tz))</measure>
    <time_frame>Day 4 and 7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmin,ss (minimum measured concentration of the analyse in plasma at steady state over a uniform dosing interval τ)</measure>
    <time_frame>Day 4 and 7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>tmax,ss (time from last dosing to the maximum concentration of the analyse in plasma at steady state over a uniform dosing interval τ)</measure>
    <time_frame>Day 4 and 7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>t½,ss (terminal half-life, calculated from the terminal elimination rate constant)</measure>
    <time_frame>Day 4 and 7</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>CLR,ss (renal clearance at steady state following multiple dose administration)</measure>
    <time_frame>Day 4 and 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRTss (steady state mean residence time)</measure>
    <time_frame>Day 4 and 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F,ss (apparent clearance of the analyse in plasma at steady state after extravascular multiple dose administration)</measure>
    <time_frame>Day 4 and 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vz/F,ss (apparent volume of distribution during the terminal phase at steady state following extravascular administration)</measure>
    <time_frame>Day 4 and 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in activated partial thromboplastin time (aPTT)</measure>
    <time_frame>Day 4 and 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in ecarin clotting time (ECT)</measure>
    <time_frame>Day 4 and 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Adverse Events</measure>
    <time_frame>up to 10 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>BIBR 1048 MS without Pantoprazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>150 mg BIBR 1048 MS capsules administered twice daily over 6 days and once in the morning of the seventh day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BIBR 1048 MS with Pantoprazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>150 mg BIBR 1048 MS capsules administered twice daily over 6 days and once in the morning of the seventh day together with Pantoprazole. Pantoprazole administration (40 mg bid) started two days before administration og BIBR 1048 and ended in the morning of the seventh day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIBR 1048 MS</intervention_name>
    <description>BIBR 1048 MS capsule 150 mg</description>
    <arm_group_label>BIBR 1048 MS without Pantoprazole</arm_group_label>
    <arm_group_label>BIBR 1048 MS with Pantoprazole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pantoprazole</intervention_name>
    <description>Pantoprazole tablet 40 mg</description>
    <arm_group_label>BIBR 1048 MS with Pantoprazole</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male and female elderly subjects as determined by results of screening

          -  Signed written informed consent in accordance with GCP and local legislation

          -  Age ≥ 65, no upper limit

          -  BMI ≥ 18.5 and ≤ 29.9 kg/m2

        Exclusion Criteria:

          -  Any finding at the medical examination (including blood pressure, pulse rate and ECG)
             deviating from normal and of clinical relevance

          -  Clinically relevant gastrointestinal, hepatic, renal, respiratory, cardiovascular,
             metabolic, immunologic, hormonal disorders

          -  History of relevant orthostatic hypotension, fainting spells and blackouts

          -  Diseases of the central nervous system (such as epilepsy) or psychiatric disorders

          -  Chronic or relevant acute infections

          -  History of

               -  allergy/hypersensitivity (including drug allergy) which is deemed relevant to the
                  trial as judged by the investigator

               -  any bleeding disorder including prolonged or habitual bleeding

               -  other hematologic disease

               -  cerebral bleeding (e.g. after a car accident)

               -  cranio-cerebral trauma

          -  Intake of drugs with a long half-life (&gt; 24 hours) within 1 month prior to
             administration

          -  Use of any drugs that might influence the results of the trial within 10 days prior to
             administration or during the trial

          -  Participation in another trial with an investigational drug within 2 months prior to
             administration or during trial

          -  Smoker (&gt; 10 cigarettes or 3 cigars or 3 pipes/day) or inability to refrain from
             smoking on study days

          -  Alcohol intake (&gt;30 - 40 g/day)

          -  Drug abuse

          -  Blood donation within 1 month prior to administration or during the trial

          -  Excessive physical activities within 5 days prior to administration or during the
             trial

          -  Any laboratory value outside the clinically accepted reference range

          -  History of any familial bleeding disorder

          -  Thrombocytes &lt; 140000/μl (male) or &lt; 156000/μl (female)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 20, 2014</study_first_submitted>
  <study_first_submitted_qc>June 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 25, 2014</study_first_posted>
  <last_update_submitted>June 24, 2014</last_update_submitted>
  <last_update_submitted_qc>June 24, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 25, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pantoprazole</mesh_term>
    <mesh_term>Dabigatran</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

